New combo aims to boost survival in tough bile duct cancer
NCT ID NCT07437287
First seen Mar 03, 2026 · Last updated May 14, 2026 · Updated 13 times
Summary
This study tests whether adding the drug Mitazalimab to standard chemotherapy helps people with advanced bile duct cancer live longer. About 160 adults whose cancer has spread or cannot be removed will take part. They will receive either chemo alone or chemo plus Mitazalimab, and be monitored for side effects and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER (BTC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
APHM - CHU La Timone
Marseille, France
-
APHP - Hopital Beaujon
Paris, France
-
CHU Brest
Brest, France
-
CHU Estaing
Clermont-Ferrand, France
-
CHU Grenoble Alpes
Grenoble, France
-
CHU Hotel Dieu
Nantes, France
-
CHU Lille
Lille, France
-
CHU Montpellier - Hôpital Saint Eloi
Montpellier, France
-
CHU Poitiers
Poitiers, France
-
CHU Tours
Tours, France
-
CHU de Bordeaux - Hopital Haut Leveque
Bordeaux, France
-
CHU de Dijon
Dijon, France
-
CHU de Lyon
Lyon, France
-
Centre Eugène Marquis
Rennes, France
-
Centre François Baclesse
Caen, France
-
Centre Léon Bérard
Lyon, France
-
Centre Paul Strauss
Strasbourg, France
-
Hopital du Confluent
Nantes, France
-
Institut Curie
Paris, France
-
Institut Jean Godinot
Reims, France
-
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France
-
Institut de cancérologie de l'Ouest - Site Paul Papin
Angers, 49933, France
Conditions
Explore the condition pages connected to this study.